Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma, Inc. (Nasdaq: CUE) is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts and focused on developing injectable biologics that selectively engage disease-specific T cells. News about Cue Biopharma often centers on its Immuno-STAT platform, clinical data from its CUE-100 series programs, and progress in autoimmune disease and oncology.
Investors and followers of CUE stock can use this page to review company press releases and third-party coverage related to Cue Biopharma’s pipeline. Typical updates include clinical trial readouts for CUE-101 in HPV16+ head and neck cancer and CUE-102 in WT1-expressing tumors, as well as developments around CUE-401, the company’s lead autoimmune asset designed to promote regulatory T cell–mediated tolerance.
News flow also highlights Cue Biopharma’s strategic collaborations and corporate milestones. Examples include agreements with Boehringer Ingelheim for CUE-501, a differentiated B cell depletion therapy for autoimmune and inflammatory diseases, and a collaboration and license agreement with ImmunoScape to advance a Seed-and-Boost cell therapy approach for solid tumors using the CUE-100 series. Financial updates, such as quarterly results, collaboration revenue disclosures and public equity offerings under the company’s shelf registration statement, are also common topics.
By following this CUE news feed, readers can track regulatory interactions, investigator-sponsored trials, leadership transitions, licensing deals and financing activities that may influence Cue Biopharma’s development trajectory. Bookmark this page to quickly access the latest headlines and historical announcements related to Cue Biopharma and its Immuno-STAT-based biologics.
Cue Biopharma (CUE) has appointed Tamar Howson to its board of directors, enhancing its business development capabilities. Howson, a veteran in the biopharmaceutical industry with over 30 years of experience, has held significant roles in renowned companies. Her expertise is anticipated to significantly aid Cue Biopharma's corporate development efforts in targeted immunotherapy. This leadership change aims to strengthen the company's strategic execution and foster growth as it advances its proprietary platform, Immuno-STAT™, designed to engage targeted T cells effectively.
On September 15, 2020, Cue Biopharma announced the publication of groundbreaking preclinical data in Nature Methods focusing on their Immuno-STAT platform, which utilizes dimeric protein scaffolds for targeted detection of tumor antigen-specific T cells. This innovative immuno-positron emission tomography (immunoPET) approach enhances the ability to visualize T cells within tumors, potentially transforming treatment methodologies for cancer and other diseases. The feasibility of using these techniques for prognostics and diagnostics was also highlighted, showcasing strong clinical implications.
Cue Biopharma (NASDAQ: CUE) announced its participation in several healthcare conferences, including the Baird Global Healthcare Conference on September 9, Morgan Stanley Global Healthcare Conference on September 17, and Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 23, 2020. The company will present its Immuno-STAT™ platform and updates on its pipeline, focusing on its lead candidate CUE-101 for HPV16-driven head and neck cancer. For more details, visit www.cuebiopharma.com.
Cue Biopharma (CUE) reported positive progress in its Phase 1 trial for CUE-101, aimed at treating HPV+ head and neck cancer. The company successfully completed dosing cohorts 4 and 5 and is moving to cohort 6. Financially, Cue Biopharma reported $1.1 million in collaboration revenue for Q2 2020, with R&D expenses increasing to $8.1 million, reflecting growing clinical costs. As of June 30, 2020, the company has $85 million in cash and marketable securities, ensuring funding for ongoing development through 2022.
On August 24, 2020, Cue Biopharma (NASDAQ: CUE) announced a poster presentation of its Neo-STAT biologics at the 16th Annual PEGS Boston Summit. This next-generation platform targets tumor-specific T cells with enhanced antigen modularity, enabling incorporation of diverse T cell epitopes. The presentation, led by Dr. Ahmet S. Vakkasoglu, will occur from August 31 to September 4, 2020. The Neo-STAT platform aims to advance cancer immunotherapy while exploring applications for infectious diseases. Cue Biopharma is focused on transforming treatment strategies through its proprietary Immuno-STAT technology.
Cue Biopharma announced the publication of novel research on immune modulation, focusing on the PD-L1:B7-1 co-inhibitory immune complex. Conducted at Albert Einstein College of Medicine, the study enhances Cue's Immuno-STAT and Neo-STAT platforms, which are designed to engineer T cells for targeted therapies in cancer and autoimmune diseases. The ongoing Phase 1 trial of CUE-101 shows promising early results, including safety and tolerability, alongside encouraging pharmacokinetic and pharmacodynamic metrics.
On June 15, 2020, Cue Biopharma announced progress in its Phase 1 trial of CUE-101 for HPV+ recurrent and metastatic head and neck squamous cell carcinoma. The trial has enrolled 13 patients, with ongoing data generation showing dose-proportional increases in drug exposure and evidence of selective T cell expansion. Preliminary results indicate clinical activity, with one patient experiencing stable disease after treatment. The drug has been well-tolerated, with primarily mild adverse events. Further patient enrollment at the 1.0 mg/kg dose is planned to refine CUE-101's therapeutic window.
Cue Biopharma, Inc. (CUE) provided a business update for Q1 2020, reporting collaboration revenue of $0.9 million, up from $0.4 million in Q1 2019. R&D expenses rose to $9.9 million due to ongoing clinical trials, including the CUE-101 mono-therapy and a collaboration with Merck on KEYTRUDA®. The company ended the quarter with a net loss of $12.8 million, slightly higher than the previous year. Cue Biopharma raised $34.3 million through an ATM offering in April, enhancing its cash position amidst pandemic challenges.
Cue Biopharma (CUE) announced a poster presentation at the AACR Virtual Annual Meeting II, showcasing pre-clinical data on its drug candidates CUE-102/A02 and CUE-102/A24 from the CUE-100 series. These Immuno-STATs™ selectively target Wilms’ tumor 1 (WT1) specific T cells for cancers like AML and breast cancer. The presentation, led by Dr. Saso Cemerski, will occur on June 22, 2020. The CUE-100 series aims to engage T cells directly in patients, potentially reducing toxicities seen in traditional therapies. Cue Biopharma is focused on transforming cancer treatment with its innovative approach.
Cue Biopharma (NASDAQ: CUE) has announced a research collaboration with Dr. Michael Dustin and the University of Oxford to explore the IL-2-based CUE-100 series Immuno-STAT biologics. This partnership aims to investigate molecular mechanisms of T cell activation and modulation related to cancer treatment. The findings are expected to enhance understanding of the mechanism of action of the lead asset, CUE-101, currently in clinical trials for head and neck cancer, potentially advancing the development of new therapies for solid and hematological cancers.
FAQ
What is the current stock price of Cue Biopharma (CUE)?
What is the market cap of Cue Biopharma (CUE)?
